Answers are grounded in this paper and cite their sources.
SHP2, a protein tyrosine phosphatase (PTP) crucial in Ras-MAPK signaling, is associated with various human congenital diseases and cancers. Here, we show that the catalytically inactive Shp2 C459S mutation results in communicating hydrocephalus, similar to the catalytically activating Shp2 E76K and Mek1 DD mutants. Unlike previous mutants, however, Shp2 C459S/+ mutation uniquely affects ciliary development rather than neurogenesis, leading to structural abnormalities in cilia and impaired ciliary motility. Differential scanning fluorimetry suggested that SHP2 C459S , SHP2 E76K , and SHP2 C459S/E76K mutations all induce an open SHP2 conformation, but only SHP2 C459S leads to aberrant GAB1 phosphorylation in cells expressing wild-type SHP2. Consistent with this distinct signaling profile, brain ventricular tissues from Shp2 C459S/+ mice exhibit elevated GAB1 and AKT phosphorylation despite normal ERK and STAT3 activities, implicating dysregulated PI3K–AKT signaling in the pathogenesis of hydrocephalus. Importantly, pharmacological inhibition of PI3K markedly rescues ciliogenesis defects and alleviates hydrocephalus in mutant mice. Furthermore, the allosteric SHP2 inhibitor SHP099 increases the thermal stability of SHP2C459S protein, consistent with a shift toward a closed state, and ameliorates hydrocephalus in Shp2 C459S/+ mice. These findings suggest that, in this engineered mouse model, Shp2 -associated hydrocephalus is driven by conformational changes rather than altered catalytic activity. Our results underscore the therapeutic potential of conformation-specific allosteric inhibitors in targeting both catalytically active and inactive SHP2 mutants.
No takes yet. Share an insight, caveat, or question.
Makrides et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: